MedTrace Logo

Frailty in the Elderly Oncological and Oncohematological Patient.

NCT07624370 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2026-06-08

No results posted yet for this study

Summary

The Italian population is progressively aging, and cancer incidence increases with age. Older patients are at higher risk of frailty, a condition associated with adverse outcomes such as disability, falls, hospitalization, and mortality.

Key indicators of frailty include reduced balance, impaired physical activity, cognitive decline, and particularly sarcopenia, defined as the progressive loss of skeletal muscle mass and strength. After age 60, muscle mass decreases by 1.4-2.5% annually, while muscle strength declines by 15% between ages 60-70 and by up to 30% per decade thereafter.

Sarcopenia increases the risk of falls, fractures, hospitalization, and non-cancer-related death. In cancer patients, its prevalence ranges from 11% to 74% and is associated with poorer survival outcomes in both early and advanced disease stages.In clinical oncology practice, several tools are available to assess frailty, identify vulnerable patients, and personalize care, treatment, and supportive interventions.

Conditions

  • Sarcopenia in Elderly
  • Frailty/Sarcopenia
  • Oncological Patients
  • Hematologic Disease

Interventions

OTHER

Frailty evaluation

Evaluation of the frailty impact on the toxicity grade 3-4 in patients undergoing chemotherapy treatment.

Sponsors & Collaborators

  • Azienda Socio Sanitaria Territoriale Ovest Milanese, Ospedale di Legnano

    lead OTHER

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-21
Primary Completion
2026-04-09
Completion
2028-12-13

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07624370 on ClinicalTrials.gov